Table 3 Microcirculatory parameters, near-infrared spectroscopy-derived variables, and glycocalyx variables (baseline and 1 hour after blood transfusion)
Non-leukodepleted group | Leukodepleted group | |||||
|---|---|---|---|---|---|---|
n = 10 | n = 10 | |||||
Before | After | P a | Before | After | P a | |
MFI, AU | 2.75 (2.43–2.87) | 2.62 (2.38–3.00) | 0.73 | 2.79 (2.37–2.92) | 2.96 (2.89–3.00) | 0.04 |
De Backer score, 1/mm | 11.3 (9.7–11.8) | 11.3 (9.3–14.4) | 0.16 | 9.8 (9.4–10.8) | 12.3 (10.6–13.1) | 0.02 |
TVD, mm/mm2 | 18.4 (16.6–19.8) | 19.6 (15.1–23.3) | 0.19 | 15.9 (12.9–19.3) | 19.3 (12.8–21.8) | 0.08 |
PVD, mm/mm2 | 16.2 (14.3–17.7) | 17.6 (13.5–21.4) | 0.23 | 14.1 (11.8–17.2) | 18.8 (12.1–21.2) | 0.04 |
PPV, % | 88.5 (83.1–93.1) | 90.6 (85.8–96.6) | 0.32 | 94.6 (82.9–95.9) | 96.8 (94.7–98.9)b | 0.01 |
HI | 0.23 (0.13–0.50) | 0.16 (0.00–0.32) | 0.31 | 0.13 (0.06–0.23) | 0.04 (0.00–0.10) | 0.11 |
Blood flow velocity, μm/s | 415 (327–494) | 291 (264–314) | 0.03 | 314 (267–354) | 402 (355–451)b | 0.08 |
THI, AU | 10.5 (7.8–11.2) | 13.4 (10.4–15.8) | <0.01 | 10.3 (8.6–13.6) | 13.8 (10.6–15.7) | 0.02 |
StO2, % | 88 (80–90) | 90 (85–93) | 0.03 | 83 (77–92) | 86 (82–89) | 0.59 |
StO2 down, %/min | −9.5 (−11 to −8.5) | −9.0 (−10.4 to −7.5) | 0.03 | −10.1 (−12.8 to −6.9) | −9.2 (−10.4 to −7.6) | 0.56 |
StO2 up, %/min | 173.6 (81.26–220.4) | 191.3 (133.4–242.4) | 0.01 | 197.9 (99.2–260.3) | 206.2 (131.1–291.8) | 0.03 |
AUC StO2, %×min | 10.7 (8.4–21) | 10.9 (8.2–25.4) | 0.99 | 8.0 (4.4–13.8) | 12.1 (5.5–18.3) | 0.51 |
PBR, μm | 2.69 (2.53–2.94) | 2.72 (2.65–2.86) | 0.23 | 2.80 (2.76–2.97) | 2.74 (2.58–3.00) | 0.73 |
Syndecan–1, ng/mL | 219.4 (84.5–361.5) | 310.1 (80.9–498.8) | 0.03 | 100.0 (5.4–378.4) | 127.5 (6.6–505.6) | 0.37 |
Heparan sulfate, ng/mL | 23.3 (19.7–39.5) | 44.7 (9.1–79.2) | 0.43 | 63.1 (40.5–96.0)b | 48.7 (39.0–79.2) | 0.37 |
Hyaluronan, ng/mL | 211.9 (75–423.7) | 198.1 (94.2–320.0) | 0.37 | 275.7 (109.3–450.7) | 249.4 (129.2–433.3) | 0.32 |